Citations

Clear

1575 citation(s) found for "Im, Gene".

Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease
Ali, Hamad , Malik, Md. Zubbair , Abu‐Farha, Mohamed , Jacob, Sindhu, Bahbahani, Yousif , Naim, Medhat, Alsayegh, Mohammad Y., Ong, Albert , Harris, Peter C. , Harris, Peter C , Ong, Albert C M , Abubaker, Jehad Ahmed , Cherian, Preethi , Nizam, Rasheeba , Ahmad, Sajjad , Thanaraj, Thangavel Alphonse , Al‐Mulla, Fahd

Mayo Clinic

The Journal of Gene Medicine | February 26, 2024 | Volume: 26 | Issue: 2 | Pages: No page available

10.1002/jgm.3674 | PMID 38404150 Get It

AbstractBackgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic renal disease progressing to end‐stage renal disease. There is a pressing need for the identification of early ADPKD biomarkers to enable timely intervention and the development of effective therapeutic approaches. Here, we profiled human urinary extracellular vesicles small RNAs by small RNA sequencing in patients with ADPKD and compared their differential expression considering healthy control individuals to identify dysregulated small RNAs and analyze downstream interaction to gain insight about molecular pathophysiology.MethodsThis is a cross‐sectional study where urine samples were collected from a total of 23 PKD1‐ADPKD patients and 28 healthy individuals. Urinary extracellular vesicles were purified, and small RNA was isolated and sequenced. Differentially expressed Small RNA were identified and functional enrichment analysis of the critical miRNAs was performed to identify driver genes and affected pathways.ResultsmiR‐320b, miR‐320c, miR‐146a‐5p, miR‐199b‐3p, miR‐671‐5p, miR‐1246, miR‐8485, miR‐3656, has_piR_020497, has_piR_020496 and has_piR_016271 were significantly upregulated in ADPKD patient urine extracellular vesicles and miRNA‐29c was significantly downregulated. Five ‘driver’ target genes (FBRS, EDC3, FMNL3, CTNNBIP1 and KMT2A) were identified.ConclusionsThe findings of the present study make significant contributions to the understanding of ADPKD pathogenesis and to the identification of novel biomarkers and potential drug targets aimed at slowing disease progression in ADPKD.
Induction of p16Ink4a Gene Expression in Heme Protein–Induced AKI and by Heme: Pathophysiologic Implications
Nath, Karl A. , Singh, Raman Deep , Croatt, Anthony J., Ackerman, Allan W., Grande, Joseph P. , O’Brien, Daniel R. , Adams, Christopher M. , Kirkland, James L. , Garovic, Vesna D , Tchkonia, Tamara, Kirkland, James L , Adams, Christopher M , Garovic, Vesna D. , Tchkonia, Tamar

Mayo Clinic

Kidney360 | February 21, 2024 | Volume: 5 | Issue: 4 | Pages: 501-514

10.34067/kid.0000000000000395 | PMID 38379160 Get It

Key Points In heme protein–mediated AKI (HP-AKI), a senescence phenotype promptly occurs, and increased expression of p16 Ink4a contributes to HP-AKI. Renal p16 Ink4a expression is induced by hemoglobin, myoglobin, and heme in vivo and in renal epithelial cells exposed to heme in vitro . Impairing the binding or degradation of heme by hemopexin deficiency or heme oxygenase-1 deficiency, respectively, further upregulates p16 Ink4a . Background Understanding the pathogenetic basis for AKI involves the study of ischemic and nephrotoxic models of AKI, the latter including heme protein–mediated AKI (HP-AKI). Recently, interest has grown regarding the role of senescence as a mechanism of kidney injury, including AKI. We examined whether senescence occurs in HP-AKI and potential inducers of and the role of a key driver of senescence, namely, p16 Ink4a , in HP-AKI. Methods The long-established murine glycerol model of HP-AKI was used, and indices of senescence were examined. To evaluate the interaction of heme and p16 Ink4a expression, murine models of genetic deficiency of hemopexin ( HPX ) and heme oxygenase-1 ( HO-1 ) were used. To determine the involvement of p16 Ink4a in HP-AKI, the population of p16 Ink4a -expressing cells was reduced using the INK-ATTAC model. Results Using multiple indices, a senescence phenotype appears in the kidney within hours after the induction of HP-AKI. This phenotype includes significant upregulation of p16 Ink4a . p16 Ink4a is upregulated in the kidney after the individual administration of myoglobin, hemoglobin, and heme, as well as in renal epithelial cells exposed to heme in vitro . Genetic deficiencies of HPX and HO-1 , which, independently, are expected to increase heme content in the kidney, exaggerate induction of p16 Ink4a in the kidney and exacerbate HP-AKI, the latter shown in the present studies involving HPX −/− mice and in previous studies involving HO-1 −/− mice. Finally, reduction in the population of p16 Ink4a -expressing cells in the kidney improves renal function in HP-AKI even within 24 hours. Conclusions The pathogenesis of HP-AKI involves senescence and the induction of p16 Ink4a , the latter driven, in part, by hemoglobin, myoglobin, and heme.
Canalicular-Like Pleomorphic Adenoma of the Parotid Gland: A Recently Classified Tumor Highlighting the Use of Frozen Section Analysis and Surrogate IHC for Gene Rearrangement Defined Subtypes
Brown, Adam E. , Hinni, Michael L., Schmitt, Alessandra C. , Eells, Annica C.

Mayo Clinic

International Journal of Surgical Pathology | February 20, 2024 | Volume: 32 | Issue: 8 | Pages: 1547-1551

10.1177/10668969241231980 | PMID 38377962 Get It

Canalicular-like pleomorphic adenomas are a relatively recently described entity, that possess features of both canalicular adenomas and pleomorphic adenomas. The presence of unusual HMGA2-fusion partners (most commonly HMGA2::WIF1 gene fusions) has established canalicular-like pleomorphic adenoma as a distinct entity. The use of intraoperative frozen section analysis and surrogate HMGA2 IHC are 2 tools that can provide the surgical team with valuable insight into intraoperative decision making and final classification of rare tumors of the parotid gland, respectively. We present a case of canalicular-like pleomorphic adenoma and characterize its appearance on frozen section analysis. HMGA2 IHC staining was retroactively performed, assisting in the confirmation of the tumor subtype.
High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing
Nooraeen, Sara , Croarkin, Paul E. , Geske, Jennifer R. , Shekunov, Julia , Orth, Scott S. , Romanowicz, Magdalena , Frye, Mark A. , Voort, Jennifer L. Vande , Vande Voort, Jennifer L , Croarkin, Paul E , Geske, Jennifer

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | February 20, 2024 | Volume: 34 | Issue: 1 | Pages: 28-33

10.1089/cap.2023.0043 | PMID 38377526 Get It

Pericyte Control of Gene Expression in the Blood-Brain Barrier Endothelium: Implications for Alzheimer’s Disease
Nelson, D.A., Wang, Lushan , Eberts, Paulina M., Azarin, Samira M. , Kandimalla, Karunya K. , Wang, Zengtao , Nelson, D. , Kandimalla, Karunya K , Thompson, Kevin J. , Wang, Zengtao , Kalari, Krishna R.

Mayo Clinic

Journal of Alzheimer’s Disease | February 20, 2024 | Volume: 99 | Issue: s2 | Pages: No page available

10.3233/jad-230907 | PMID 38393902 Get It

Background: A strong body of evidence suggests that cerebrovascular pathologies augment the onset and progression of Alzheimer’s disease (AD). One distinctive aspect of this cerebrovascular dysfunction is the degeneration of brain pericytes—often overlooked supporting cells of blood-brain barrier endothelium. Objective: The current study investigates the influence of pericytes on gene and protein expressions in the blood-brain barrier endothelium, which is expected to facilitate the identification of pathophysiological pathways that are triggered by pericyte loss and lead to blood-brain barrier dysfunction in AD. Methods: Bioinformatics analysis was conducted on the RNA-Seq expression counts matrix (GSE144474), which compared solo-cultured human blood-brain barrier endothelial cells against endothelial cells co-cultured with human brain pericytes in a non-contact model. We constructed a similar cell culture model to verify protein expression using western blots. Results: The insulin resistance and ferroptosis pathways were found to be enriched. Western blots of the insulin receptor and heme oxygenase expressions were consistent with those observed in RNA-Seq data. Additionally, we observed more than 5-fold upregulation of several genes associated with neuroprotection, including insulin-like growth factor 2 and brain-derived neurotrophic factor. Conclusions: Results suggest that pericyte influence on blood-brain barrier endothelial gene expression confers protection from insulin resistance, iron accumulation, oxidative stress, and amyloid deposition. Since these are conditions associated with AD pathophysiology, they imply mechanisms by which pericyte degeneration could contribute to disease progression.
Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene
Abozaid, Mohamed , Munankarmy, Amik , Rao, Tara, Couch, Ronan E. , Persons, Benjamin R., Pesaran, Tina , Huang, Huaizhi , Hu, Chunling , Na, Jie , Abozaid, Mohamed, Lumby, Carolyn A. , Lyra, Paulo C. , Polley, Eric C. , Karam, Rachid , Yadav, Siddhartha , Monteiro, Álvaro N.A. , Boddicker, Nicholas , Domchek, Susan M. , Richardson, Marcy E , Couch, Fergus J.

Mayo Clinic

Cancer Research | February 1, 2024 | Volume: 84 | Issue: 3_Supplement_1 | Pages: PR09-PR09

10.1158/1538-7445.advbc23-pr09 Get It

Abstract Many germline BRCA2 missense variants of uncertain significance (VUS) remain to be clinically classified as pathogenic or benign. Here we identify 70 missense VUS in the DNA binding domain (DBD) of BRCA2 that partially reduced homologous recombination DNA repair activity of the protein in a homology directed DNA repair cell-based assay. CRISPR/cas9-based knockin of these variants reduced cell survival of haploid cells and conferred increased sensitivity to the PARP inhibitor Olaparib. Sequence alignment analysis found that the variants were highly conserved across species from pufferfish to human. Structural analysis showed that these variants are located predominantly in unstructured regions of the DBD. Case-control association studies showed that the hypomorphic variants conferred moderate risks of breast (OR:2.85; 95%CI:1.43-5.88) and ovarian cancer (OR:3.37; 95%CI:1.30-8.54) that were significantly different from risks associated with known pathogenic and benign variants. Cumulative lifetime risks of breast and ovarian cancer among carriers were estimated at 25% and 4.7%, respectively. Age at diagnosis of breast cancer among hypomorphs carriers was 55 years of age as opposed to 48 years of age for carriers of pathogenic variants. In addition, the combination of functional and other genetic data in an ACMG/AMP-like variant classification model reclassified 39 variants as likely pathogenic. This novel group of low penetrance missense variants further calibrate BRCA2 variant classification methods and have significant implications for the management of variant carriers. Citation Format: Huaizhi (Gilbert) Huang, Chunling Hu, Jie Na, Mohamed Abozaid, Amik Munankarmy, Tara Rao, Carolyn A. Dunn Lumby, Paulo Cilas Morais Lyra, Ronan E. Couch, Benjamin R. Persons, Eric C. Polley, Rachid Karam, Tina Pesaran, Siddhartha Yadav, Alvaro N.A. Monteiro, Nicholas J. Boddicker, Susan M. Domchek, Marcy E. Richardson, Fergus J. Couch. Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr PR09.
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value
Battaglin, Francesca , Millstein, Joshua , Yang, Yan , Xiu, Joanne , Arai, Hiroyuki , Wang, Jingyuan , Innocenti, Federico , Kawanishi, Natsuko , Lenz, Annika , Algaze, Sandra , Zhang, Wu, Khoukaz, Taline, Torres, Evanthia T. Roussos , Seeber, Andreas , Abraham, Jim , Shields, Anthony F. , Goldberg, Richard M. , Lenz, Heinz‐Josef , Arai, Hiroyuki , Lou, Emil , Lenz, Heinz-Josef , Baca, Yasmine , Wang, Jingyuan , Ou, Fang‐Shu , Mumenthaler, Shannon M. , Jayachandran, Priya , Soni, Shivani , Lou, Emil , Philip, Philip A. , Weinberg, Benjamin A. , Marshall, John L , Venook, Alan P. , Korn, Wolfgang Michael

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 11, 2024 | Volume: 12 | Issue: 1 | Pages: e007939

10.1136/jitc-2023-007939 | PMID 38212126 Get It

Background The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5 / CCL5 expression in CRC and to determine whether CCR5 / CCL5 levels could impact treatment outcomes. Methods 7604 CRCs tested with NextGen Sequencing on DNA and RNA were analyzed. Molecular features were evaluated according to CCR5 and CCL5 tumor gene expression quartiles. The impact on treatment outcomes was assessed in two cohorts, including 6341 real-world patients and 429 patients from the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial. Results CCR5 / CCL5 expression was higher in right-sided versus left-sided tumors, and positively associated with consensus molecular subtypes 1 and 4. Higher CCR5 / CCL5 expression was associated with higher tumor mutational burden, deficiency in mismatch repair and programmed cell death ligand 1 (PD-L1) levels. Additionally, high CCR5 / CCL5 were associated with higher immune cell infiltration in the tumor microenvironment (TME) of MMR proficient tumors. Ingenuity pathway analysis revealed upregulation of the programmed cell death protein 1 (PD-1)/PD-L1 cancer immunotherapy pathway, phosphatase and tensin homolog (PTEN) and peroxisome proliferator-activated receptors (PPAR) signaling, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) signaling in cytotoxic T lymphocytes, whereas several inflammation-related pathways were downregulated. Low CCR5 / CCL5 expression was associated with increased benefit from cetuximab-FOLFOX treatment in the CALGB/SWOG 80405 trial, where significant treatment interaction was observed with biologic agents and chemotherapy backbone. Conclusions Our data show a strong association between CCR5/CCL5 gene expression and distinct molecular features, gene expression profiles, TME cell infiltration, and treatment benefit in CRC. Targeting the CCR5/CCL5 axis may have clinical applications in selected CRC subgroups and may play a key role in developing and deploying strategies to modulate the immune TME for CRC treatment.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Zhang, Ting , Bouchonville, Kelly J. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

No container title available | January 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.1 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Temesgen, Zoey B , Stroka, Deborah , Largiadèr, Carlo R , Offer, Steven M , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

eLife | January 10, 2024 | Volume: 13 | Issue: No issue available | Pages: No page available

10.7554/elife.94075 | PMID 38686795 Get It

Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.

Mayo Clinic

Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available

10.1128/jvi.01791-23 | PMID 38168672 Get It

ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.